[4][10], In March 2022, during the Shanghai COVID-19 outbreak, the medication was distributed en masse to residents. Wang F.C., Shen B.X., He C.Y., Zhao W.C., Nie S.L. Subgroup analysis revealed that LHQW group has a reduced incidence of rash than the conventional drug group (RR = 0.58, 95% CI = 0.390.86, p = 0.007), no statistical difference was detected for itchy skin. Flow chart of the search and selection process. Kunming: Kunming University of technology. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Inclusion in an NLM database does not imply endorsement of, or agreement with, Homogeneity of baseline data was reported in most studies. The COVID-19 pneumonia epidemic has spread across the globe poses a significant challenge to public health worldwide. (2002). doi:10.1097/MD.0000000000026059, Gallelli, L., Ferreri, G., Colosimo, M., Pirritano, D., Guadagnino, L., Pelaia, G., et al. On March 27, 2019, Yiling Pharmaceutical Co. Ltd. amended the LHQW drug manual to include adverse reactions related to its clinical application. "This medicine has a cooling effect so if you take this, lalo kang magchi -chill," he cautions. Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. Drugs and Clinic. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy. [4] Its formulation includes 13 herbs which are said to have been used for medical purposes as early as the Han dynasty. In addition, LHQW capsules could inhibit both Victoria and Yamagata lineages of influenza B virus (IBV) with the 50 % inhibitive concentrations ranging from 0.2280.150 to 0.7540.161mg/mL [26]. Batlle D., Wysocki J., Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. Ephedra increases heartbeat and blood pressure. 12, 640782. doi:10.3389/fphar.2021.640782. Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. This study was supported by the COVID-19 Pneumonia of Traditional Chinese Medicine Emergency Project, State Administration of Traditional Chinese Medicine of the Peoples Republic of China (2020ZYLCYJ02-1). f. & Thoms.) Modern pharmacological studies have shown that Lianhua Qingwen Prescription, as a traditional Chinese medicine prescription, has extensive antiviral and immunomodulatory effects on a series of influenza viruses. Several limitations of our meta-analysis should be taken into consideration. recently published a clinical study on the treatment of mild COVID-19 with LHQW granules (6g, tid) combined with abidor (0.2g, tid) [44]. 161, 105126. doi:10.1016/j.phrs.2020.105126, Yang, C., Wang, Y., He, J., Yan, W., Jiang, H., Chen, Q., et al. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools. Now, there are no study results posted on ClinicalTrials.gov for this study yet. Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. Recently, Yu et al. [4][7], Lianhua Qingwen should be avoided for patients with G6PD deficiency, since its active ingredient, Lonicera japonica, will lead to hemolysis to such patients. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). Res. Traditional Chinese medicine treatment maintains homeostasis through interactions between the body and pathogens or establishing a balance between stimulating antiviral responses and suppressing overactive immune responses that leads to tissue damage (Shi et al., 2021). These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. National Administration of Traditional Chinese Medicine: Traditional Chinese Medicine Is Involved in a Wide Range of Treatment and Early Intervention Has Good Effects. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). (2021) investigated the efficacy and security of LHQW in the treatment of mild or moderate COVID-2019 pneumonia, reported no statistical difference in the incidence of adverse reactions between LHQW and conventional treatment groups from two studies (RR = 0.43, 95%CI = 0.121.54, p = 0.19). Med. Pharmacol. [Fabaceae; Glycyrrhizae Radix et Rhizoma] (85g) (Rivera et al., 2014; Royal Botanic Gardens, Kew, 2021; Royal Botanic Gardens, Kew science, 2021; The Plant List, 2021; Yiling Pharmaceutical, 2021). Pharmacol. 'medicine using forsythia suspensa and lonicera japonica to clear illness',[1] LHQW) is a traditional Chinese medicine (TCM) formulation used for the treatment of influenza. The participants, interventions, comparison, outcome and study design (PICOS) criteria were used to identify articles: 1) participants: patients treated with LHQW, 2) interventions: LHQW or LHQW combined with conventional drug (LHQW capsule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20040063; LHQW granule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20100040), 3) comparison: conventional drugs, including antiviral drugs, conventional antibiotics or symptomatic treatment, 4) outcome: relevant data on adverse reactions, and 5) study design: experimental study. Similar results were obtained in subgroup analysis of hepatic function abnormal and transaminase increased. Future related studies will provide accumulated evidence to clarify it. Wang L., Yang Z.H., Zhang H.R., Yu H.X., Yang K., Fu B.H., Yang H.T. [5], Sources of its formulation reportedly consist of:[6], The medicine is both in capsule and granular form. The majority of studies lacked sufficient description of allocation concealment and therefore, the project was predominantly evaluated as unclear risk of bias. Although the blinding method was not reported, since some symptom indicators needed measurement with instruments, assessment of symptom indicators was unlikely to be affected by the lack of blinding. Sensitivity analysis was performed by assessing the stability of the results after removal of individual studies. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Keywords: Lianhua Qingwen capsule; Meta-analysis; influenza; systematic review. Upon full text filtering of the remaining 715 citations, 498 were excluded due to a number of reasons (shown in Figure 1). BMJ. Evid. Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. No use, distribution or reproduction is permitted which does not comply with these terms. Covid-19: an Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. the contents by NLM or the National Institutes of Health. In our meta-analysis, information on adverse reactions was clearly reported in 12 of the 17 studies while the remaining five studies provided no specific evidence of adverse reaction specifically, and the incidence of adverse reactions was lower in LHQW group than that in the conventional drug group. DerSimonian, R., and Laird, N. (1986). Chinese Pharmacopoeia (2020). The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. No statistical difference was detected for sleepy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. Ping F., Li Z., Zhang F., Li D., Han S. Effects of Lianhua Qingwen on pulmonary oxidative lesions induced by fine particulates (PM2.5) in rats. Theoretical Study of the Anti-ncp Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (Lqf). [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. Compared with the conventional drug group, the incidence of disease recurrence was lower in the LHQW group, implied that LHQW might could regulate and enhance the immune function of the body. Subgroup analysis additionally demonstrated LHQW group has a reduced incidence of rash, nausea or vomiting, and resurgence of disease. Meta-analysis and systematic review of efficacy and safety of Lianhua Qingwen in adjuvant treatment of adult pneumonia. (2015). 20 studies documented other adverse reactions. Anal. The quadruple combination therapy including Ribavirin, Lopinavir/ritonavir, Umifenovir, and LHQW, could markedly improve the abnormal coagulation and leukocyte of severe COVID-19 patients with a better prognosis [42]. Adverse Drug Reactions to Antibiotics Observed in Two Pulmonology Divisions of Catanzaro, Italy: a Six-Year Retrospective Study. In the evaluation of security indexes, LHQW group has a reduced incidence of respiratory system damage, skin and its appendages injury, nervous system damage and gastrointestinal system damage, along with other adverse reactions. HHS Vulnerability Disclosure, Help Formulae. It cannot be taken as prophylaxis or as a health supplement. Lianhua Qingwen Capsules/granules Product Details. The site is secure. Avoid prolonged use. (2021). aimed to assess the efficacy and safety of LH combined with usual treatment vs usual treatment alone in treating mild or moderate COVID-19 by a meta-analysis of randomized controlled trials (RCTs). A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. Chin. Emerging data have also shown its beneficial effects in treating diverse diseases such as acute respiratory infection, influenza, pneumonia, hand-foot-mouth disease, chronic obstructive pulmonary disease (COPD), as well as COVID-19 [[20], [21], [22], [23]]. Wu et al. Additionally, LHQW group also had shorter time to recovery of fever, fatigue and coughing, and higher improvement rate in chest computed tomographic manifestations and clinical cure [43].
September Born Personality,
Property Management Letter To Tenants About Parking,
Grout Line Size For 3x6 Subway Tile,
Michael Mays Obituary,
Articles L